Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Conditions

Neuroendocrine Tumors 11Neoplasms 8Carcinoid Tumor 7Diarrhea 6Colorectal Neoplasms 6Carcinoma, Hepatocellular 5Vipoma 4Stomach Neoplasms 4Somatostatinoma 4Rectal Neoplasms 4Insulinoma 4Glucagonoma 4Gastro-enteropancreatic neuroendocrine tumor 4Carcinoma, Islet Cell 4Breast Neoplasms 4Adenoma, Islet Cell 4Acromegaly 4Weight Loss 3Prostatic Neoplasms 3Pancreatic Neoplasms 3Neoplasm Metastasis 3Intestinal Obstruction 3Gastrinoma 3Esophageal Neoplasms 3Colonic Neoplasms 3Carcinoma 3Thymoma 2Pituitary Neoplasms 2Ovarian Neoplasms 2Meningioma 2

Interventions

Cyclophosphamide 153Dexamethasone 140Rituximab 83fludarabine 79Cytarabine 69Lenalidomide 68Bortezomib 64fludarabine phosphate 62Gemcitabine 62venetoclax 55Etoposide 53pembrolizumab 52pomalidomide 49Paclitaxel 48Cisplatin 47Carboplatin 47Peripheral Blood Stem Cell Transplantation 46Filgrastim 40Radiotherapy 39Calcium Dobesilate 36Busulfan 36Methotrexate 34Melphalan 34Bevacizumab 33carfilzomib 32Cyclosporine 32Azacitidine 32Mycophenolic Acid 29Vincristine 28Temozolomide 28

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Recurrence × Octreotide × Clear all
NCT06865677 2026-01-21

Sacituzumab Govitecan for Relapsed Ovarian, Endometrial, and Cervical Carcinomas

National Institutes of Health Clinical Center (CC)

Phase 2 Terminated
2 enrolled 7 charts

Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon âš¡